Similar articles

• Redistribution of cardiac output to the kidneys during oral nadolol administration.

  Textor SC, Fouad FM, Bravo EL, Tarazi RC, Vidt DG, Gifford RW Jr. Textor SC, et al. N Engl J Med. 1982 Sep 2;307(10):601-5. doi: 10.1056/NEJM198209023071007. N Engl J Med. 1982. PMID: 7110207 No abstract available.
• Isometric exercise before and after nadolol treatment in uncomplicated essential hypertension.

  Corea L, Bentivoglio M, Provvidenza M. Corea L, et al. Int J Clin Pharmacol Res. 1984;4(1):35-40. Int J Clin Pharmacol Res. 1984. PMID: 6469432
• Treatment of portal hypertension with nadolol in patients with liver cirrhosis.

  Cervera J, Torres-Zamora M, Gutiérrez-Carreño R, Fierro M, Schaeffer L, Landa L. Cervera J, et al. Arch Invest Med (Mex). 1983 Oct-Dec;14(4):331-41. Arch Invest Med (Mex). 1983. PMID: 6678555 English, Spanish. No abstract available.
• [Controlled study of the antihypertensive efficacy of the combination of nadolol and bendroflumethiazide with respect to nadolol alone and placebo].

  Cherchi A, Sau F, Mercuro G, Seguro C, Lai O. Cherchi A, et al. Clin Ter. 1985 May 31;113(4):301-6. Clin Ter. 1985. PMID: 3893868 Clinical Trial. Italian. No abstract available.
• Influences of dibutyryl cyclic adenosine monophosphate and forskolin on human sperm motility in vitro.

  Liu JH, Li Y, Cao ZG, Ye ZQ. Liu JH, et al. Asian J Androl. 2003 Jun;5(2):113-5. Asian J Androl. 2003. PMID: 12778321